News | August 11, 2021
Lupin posts net profit of Rs 542.46 cr. in Q1FY22
The profits were bolstered by the Boehringer Ingelheim MEK program income
The profits were bolstered by the Boehringer Ingelheim MEK program income
A globally approved pen filled by mass technology provides a safer self- administration fertility solution
Deal signed with AOP Orphan for US commercial rights
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Founded in 2019, the start-up develops digital therapeutics, a therapeutic intervention from the convergence of biology and information technology
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
The transaction is expected to close in the Q4FY22
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
MitraClip implants give a new lease of life for frail and elderly patients who cannot go in for conventional open-heart surgery
Subscribe To Our Newsletter & Stay Updated
